Kornimate/medical-research-clean huggingface dataset:
iconographies for risk communication and reduction of patient's anxiety in a colorectal cancer screening program

Conditions: Colo-rectal Cancer

Summary: background: participants in the colon and rectal cancer (crc) screening program that have a positive result in the fecal immunological test (fit) are visited by the screening nurse who explains the meaning of the positive test and the need to perform a colonoscopy. having a positive result in the screening test can have a negative psychological impact on patients causing anguish. objective: to evaluate whether the use of iconographies to communicate the risks of possible diagnoses to patients with positive fit improves the understanding of the information and reduces the degree of anguish. methods: quasi-experimental pre-post intervention study with a control group. 240 individuals (men and women between 50-69 years of age, with a positive fit result attending the nursing visit) will be included in two non-concurrent study groups (120 individuals per group). the control group will receive the nurse visit as usual. for the intervention group, the nurse will use iconographies to communicate the risk of the different possible diagnoses and the risk of complications of the colonoscopy. the degree of distress (distress thermometer and a scale of emotion-faces) will be measured before and after the visit and the understanding of the information (visual analog scale) after the visit. the degree of distress between the control group and intervention group will be compared. if the results are favorable, the systematic use of iconographies can be implemented in the nursing screening visit and be extended to other screening units.


Eligibility criteria:
inclusion criteria: * women and men and * between 50 and 69 years of age and * who participate in the colorectal cancer screening program and have a positive result in the fit and * who attend the nursing visit. exclusion criteria: * people who do not understand catalan or spanish or * with cognitive deterioration that prevents them from answering a questionnaire or * who do not know how to read or write.

Keywords: colorectal cancer screening iconographies risk communication patient medical knowledge
functional remediation for bipolar disorder

Conditions: Bipolar Disorder

Summary: bipolar disorder is a severe, chronic and recurrent illness, that affects nearly the 5% of the population. recent research point at the relevance and persistence of cognitive dysfunctions in bipolar patients even beyond the acute phases, although cognitive impairment has been classically associated with schizophrenia and not bipolar disorder. current findings suggest that some intervention is needed in order to improve not only affective symptoms but also cognitive dysfunctions, so that patients could benefit from cognitive remediation techniques to improve cognitive impairment and the functional outcome. there is no previous research on the efficacy of cognitive remediation programs on bipolar disorder.

the method consists of a randomized clinical trial with 3 arms: 1) one group (n=66) will receive a cognitive rehabilitation program + pharmacological treatment, 2) another group (n=66) will receive a psychoeducation program + pharmacological treatment, and 3) a control group (n=66) will only receive pharmacological treatment. a psychopathological, neuropsychological and functional assessment will be administered pre and post-intervention and a 12-month follow-up to assess the long term effects of the intervention.

Eligibility criteria:
inclusion criteria: * outpatients * diagnosis of bipolar disorder type i or ii, according to dsm-iv-tr 4ª ed criteria * adult patients, aged between 18 and 55 years old * euthymic (ymrs \< 6, hdrs \< 8) for at least three months prior to study entry. * signed inform consent * severe or moderate functional impairment (fast \> 18) exclusion criteria: * iq \< 85 * neurological illness * present diagnosis of substance abuse or dependence according to dsm-iv criteria the last three months * significant medical illness considered as severe by the study that may interfere with assessments * having been enrolled in any kind of cognitive rehabilitation intervention the last two years

Keywords: functional remediation psychoeducation neurocognition
assessing how normal variations in ct scanning affects its interpretation

Conditions: Colorectal Cancer Metastatic

Summary: the purpose of the study is to see how measurements of tumor differences vary with slight changes in ct scan parameters. reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical ct scanners even in the setting of variable scan parameters and variable contrast timing. participants will be consented to undergo an additional ct of their abdomen.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age on the day of signed informed consent * patients scheduled and approved for contrast enhanced ct that includes imaging of the abdomen and pelvis following the department of radiology standard of care protocol as per local institutional guidelines * patients with measurable colorectal liver metastases on prior imaging, with at least one tumor greater than 2.0 cm in axial maximal diameter exclusion criteria: * patient who is pregnant and/or lactating * patient scheduled for ct that includes the abdomen with a multiphasic contrast enhanced protocol (e.g. triple phase or quadruple phase liver ct) * patient who require reduced intravenous contrast dose based on the department of radiology contrast policy as per local institutional guidelines * any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or follow up procedures

Keywords: colorectal liver metastases ct scan 17-010
research of intensive metabolic intervention before pregnancy in pcos

Conditions: PCOS; Impaired Glucose Tolerance

Summary: to investigate whether intensive metabolic intervention of pcos women before pregnancy can improve pregnancy outcome.besides, the investigators aim to investigate the best therapy strategy of metabolic intervention before pregnancy.the investigators plan to recruit pcos women at childbearing age. by using acarbose, glp-1 analogue, berberin et al. the investigators will intervent the participants' metabolic statues for 3 months before pregnancy and to compare outcome in each group.

to investigate whether intensive metabolic intervention of pcos women before pregnancy can improve pregnancy outcome.besides, the investigators aim to investigate the best therapy strategy of metabolic intervention before pregnancy.the investigators plan to recruit pcos women with igr / dm not effective of metformin treatment at childbearing age. by using acarbose, glp-1 analogue, berberin et al. the investigators will intervent the participants' metabolic statues for 3 months before pregnancy and to compare outcome in each group.

Eligibility criteria:
inclusion criteria: * pcos women at childbearing age * pcos: clinical hyperandrogenism and/or hyperandrogenemia, menstrual dysfunction (oligomenorrhea or amenorrhea) and exclusion of other known disorders. pcos will be diagnosed using the 2003 rotterdam criteria. exclusion criteria: * past or present history of a medical disorder or medication known to affect body composition, insulin secretion and sensitivity, or the growth hormone (gh)-insulin-like growth factor 1 (igf1) axis (eg steroid hormone or thyroid replacement). * history of current or past pregnancy * hormonal contraceptive or metformin use within 3 months of enrollment * nonclassical congenital adrenal hyperplasia

Keywords: pcos imparied glucose tolerance
comparison of bronchodilator treatment practices in group e copd patients

Conditions: COPD Exacerbation Acute

Summary: copd is a heterogeneous condition caused by airway (bronchitis/bronchiolitis) or alveolar (emphysema) abnormality, changes with chronic respiratory changes (dyspnea, dyspnoea, phlegm). it is characterized by persistent and frequently progressive airway obstruction. in copd, which progresses with high mortality, non-pharmacological treatments are applied, as well as pharmacological treatments. they have an essential place in slowing down the progressive course of this treatment. however, despite the treatment administered to copd patients, outdoor weather conditions, improper use of inhaler treatments, or comorbidities may cause acute exacerbation of copd. dry air nebulizer devices use dry air from the central system in hospitals. this system, which converts bronchodilator drugs into nebulizers by creating high currents, works like classical nebulizers without an electrical system and can have a higher flow rate than jet nebulizer devices. this procedure, which can be applied to copd patients without giving high-flow oxygen, prevents carbon dioxide retention. there is no study in the literature comparing the bronchodilator effectiveness of dry air, classical nebulizer, and jet nebulizer, and the investigators aimed to compare the efficacy of these three treatment modalities in our study.


Eligibility criteria:
inclusion criteria: * group e copd patients exclusion criteria: * recent mi * pulmonary embolism * cerebral aneurysm * active hemoptysis * pneumothorax * nausea, vomiting * recent thorax, abdominal, and eye surgery were identified in the patients before the pulmonary function test and were not included in the study. * mental retardation * pneumonia with acute exacerbation of copd * patients with pulmonary edema due to congestive heart failure * patients with interstitial lung disease along with copd
skeletal muscle mass used to assess frailty in older gastric cancer patients

Conditions: Gastric (Stomach) Cancer; Frailty; Sarcopenia; Malnutrition Elderly

Summary: the primary aim of this study was to quantify the diagnosis of pre-surgical skeletal muscle mass in elderly gastric cancer patients and to analyse its correlation with frailty. the second aim was to investigate whether skeletal muscle mass, or sarcopenia, is associated with mobility and nutritional status, and anxiety and depression. the main questions it aims to answer are whether skeletal muscle mass is significantly associated with frailty and whether it can be used as a brief screening tool for preoperative frailty.


Eligibility criteria:
inclusion criteria: * diagnosed with gastric cancer by endoscopy or pathology; age \>60 years old; radical gastrectomy was proposed; be able to communicate simply in writing and verbal. exclusion criteria: * received preoperative radiotherapy or chemotherapy; combined with other sites of malignant tumors; combined with severe heart, liver, lung and renal insufficiency; recent using hormones, immunosuppressants; with physical disabilities.

Keywords: gastric cancer skeletal muscle mass frailty sarcopenia
a study of hsp90 inhibitor at13387 alone or in combination with abiraterone acetate

Conditions: Prostate Cancer

Summary: a 2-part, phase 1-2, open-label, parallel group, randomized study in patients with castration-resistant prostate cancer (crpc) who are no longer responding to treatment with abiraterone and steroids. in part a (phase 1), patients will continue to receive the same doses of abiraterone and steroids they were receiving prior to study entry and will be randomized to receive 1 of 2 different treatment regimens of at13387 in combination with abiraterone. once the best regimen is established in part a, based on safety and antitumor activity, patients will be randomized to the selected treatment regimen and dose of at13387 in combination with abiraterone or at13387 alone in part b (phase 2).


Eligibility criteria:
inclusion: 1. must have prostate cancer 2. have received prior castration by orchiectomy and/or hormone therapy 3. males \>18 years of age 4. normal activity level for self care 5. have been receiving abiraterone therapy with a steroid for ≥1 month 6. have disease progression on abiraterone as defined by either psa progression, radiographic or bone progression 7. have adequate bone marrow, liver and kidney function 8. must be willing to provide pre-existing tumor samples, if this material exists. if pre-existing samples are not available, a sample must be obtained during screening 9. must be willing and able to provide written informed consent and comply with the protocol and study procedures exclusion: 1. prior anti-cancer treatment with any heat shock protein 90 (hsp90) inhibitor or histone deacetylase (hdac) inhibitor compound 2. have received chemotherapy within 4 weeks prior to receiving study drug 3. prior prostate surgery or radiotherapy within 4 weeks from the first dose of study drug 4. hypersensitivity to at13387 or other components of the drug product 5. treatment with any investigational drug within 4 weeks prior to the first dose of study drug 6. severe systemic diseases or active uncontrolled infections 7. presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors 8. abnormal heart function 9. other cancer except for adequately treated basal cell or squamous cell carcinoma of the skin, or superficial bladder cancer, or other cancer from which the subject has been disease-free for at least 3 years; 10. no known brain or cns involvement 11. unable to receive corticosteroids or history of pituitary or adrenal dysfunction 12. known history of human immunodeficiency virus (hiv) or seropositive test for hepatitis c virus or hepatitis b virus

Keywords: prostate cancer
analysis of genetic factors which may influence the course of hiv infection

Conditions: HIV Infection

Summary: patients with hiv an have a variable course of their infection. we are trying to identify factors which worsen or ameliorate the course of the disease. such factors may be related to metabolism (breakdown) of drugs or to iron handling by the body.

patients with hiv can have a variable course and the disease may be influenced by polymorphisms in drug metabolism and disposition genes such as mdr1 and cyp3a4. in addition, reports have linked changes in the course of the disease with iron status, with high iron being detrimental. we will study polymorphisms in these genes and correlate with clinical course in hiv patients and also with phenotype of drug resistance and disease parameters (such as cd4 counts and opportunistic infections).

Eligibility criteria:
inclusion criteria: * diagnosis of hiv exclusion criteria: * under 18 years of age
correlation between molecular typing and neoadjuvant chemotherapy in breast cancer patients based on mammaprint/blueprint test

Conditions: Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer

Summary: this study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by nccn, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.based on the technical analysis of mammaprint in patients with pathologic complete response (pcr), partial response and no response, we analyzed the characteristic genes related to breast cancer in tumor tissues and evaluated the accuracy and sensitivity of mammaprint test in the efficacy of neoadjuvant chemotherapy.a new model for predicting nct effect of breast cancer with combined risk genes and clinical parameters was established based on the clinical characteristic parameters of patients to study the accuracy and sensitivity of mammaprint monitoring for prognosis determination of breast cancer patients.


Eligibility criteria:
inclusion criteria: * pathologically confirmed new breast cancer (invasive cancer) * clinical stage ii-iii * women * aged 25-80 * at least 6 months of follow-up data, clinical diagnosis and treatment information and personal information available for follow-up are complete * complete biological samples required for the study: fresh/frozen tissues/white tablets/wax blocks meeting the requirements of the experiment (before neoadjuvant chemotherapy) * tumor markers and imaging data were complete * neoadjuvant chemotherapy is commonly recommended by the standard nccn guidelines exclusion criteria: * subjects refuse to participate * first diagnosis of stage i or iv breast cancer * pathological diagnosis of concurrent (or previous) other malignant tumors * prehistory breast cancer * younger than 25 or older than 80 * clinical diagnosis and treatment information or biological samples required by the research institute do not meet the needs of the experiment

Keywords: neoadjuvant chemotherapy mammaprint blueprint prognosis
corin minihip and trinity cup clinical surveillance study

Conditions: Total Hip Arthroplasty; Osteoarthritis, Hip; Traumatic Arthritis of Hip; Rheumatoid Arthritis of Hip; Developmental Dysplasia of the Hip; Avascular Necrosis of the Femoral Head

Summary: the aim of the study is to provide long term follow up data on the performance and safety of the corin minihip and trinity acetabular cup over a 10-year period.

to verify the ten-year clinical and radiographic performance of the corin minihip and trinity advanced bearing acetabular system when used in patients under normal conditions of use. to document the safety, evaluate patient satisfaction, quality of life and to determine the survivorship following intervention with the corin minihip and trinity advanced bearing acetabular system at each follow-up visit.

Eligibility criteria:
inclusion criteria: * a severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis or developmental dysplasia of the hip. * avascular necrosis of the femoral head * all subjects must be between the age of 18 and 75 at the time of surgery to take part in this study * scheduled for a primary total hip replacement. exclusion criteria: * active infection * severe obesity (bmi over 35) * pregnancy * mental illness * grossly distorted anatomy (surgeon's discretion) * sepsis * osteomyelitis * osteomalacia * distant foci of infections * osteoporosis * metabolic disorders which may impair bone formation * muscular atrophy or neuromuscular disease * allergy to implant material * marked bone loss or bone resorption * patients without sufficient quantities of synovial fluid to allow for proper lubrication, such as patients with sjogren's syndrome * skeletally immature patients and cases where there is a loss of abductor musculature, poor bone stock or poor skin coverage around the hip joint which would make the procedure inappropriate * any case not described in the inclusion criteria * any patient who cannot or will not provide informed consent for participation in the study * those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems.
phacoemulsification sleeves

Conditions: Cataract

Summary: incision size in cataract surgery is related to induced surgical astigmatism, chamber stability, and surgical efficiency. sleeves of different diameters change the size of the surgical incision and amount of fluid allowed into the eye during the surgical procedure for a given set of surgical parameters. optimization of surgical parameters requires review of surgical efficiency including: fluid usage, energy usage, and total surgical time. with optimized surgical parameters recommendations can be made to increase the efficiency and safety of cataract surgery.

no scientific data has been presented comparing the surgical efficiency of the 2.2, 2.8, and 3.0 mm diameter phacoemulsification sleeves for the alcon infinity 1.1 mm flare abs tip or the changes in surgical parameters which optimize their performance. fifty patients per sleeve group will undergo standard cataract extraction with documentation of surgical parameters used for each group. the goal of the study is to determine the most efficient surgical settings for each sleeve diameter and determine statistically the surgical parameters which optimize the use of each phacoemulsification sleeve. purpose: the goal of the study is to determine the most efficient surgical settings for each sleeve diameter and determine statistically the surgical parameters which optimize the use of each phacoemulsification sleeve. design: the study is designed to allow for scientific evaluation and publication of efficiency parameters using phacoemulsification sleeves of 2.2, 2.8, and 3.0 mm. the proposed study is a prospective nonrandomized clinical investigation of 50 patients per sleeve group. methods: data gathered at the time of surgery will include standard surgical parameters including: total surgical time, total phacoemulsification/torsional time/power, total volume of infusion fluid, aspiration level, and vacuum level. post-operative data will include: post-op day one and week three corneal clarity (clear, would edema, central edema), anterior chamber cell seen in a 2mm 16x magnified slit-lamp biomicroscopic view focused in the aqueous humor (grade 0 = 0 cells, 1 = up to 10 cells, 2 = 10 to 20 cells, 3 = 20 to 30 cells, 4 = too numerous to count), and uncorrected and/or best corrected visual acuity.

Eligibility criteria:
inclusion criteria: * requiring cataract surgery exclusion criteria: * n/a

Keywords: cataract surgery phacoemulsification sleeve
to study the safety and effectiveness of a granisetron patch to treat chemotherapy-induced nausea and vomiting (cinv)

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: to study the safety and effectiveness of a granisetron patch to treat chemotherapy-induced nausea and vomiting (cinv)


Eligibility criteria:
inclusion criteria: * patients must be of non-childbearing potential and female patients must have a negative pregnancy test at the screening visit * histologically and/or cytologically confirmed cancer with ecog ≤2 * life expectancy of ≥ 3 months * assigned to receive the first cycle of a new multi-day chemotherapy regimen including the daily administration of cytotoxic agent(s) with the emetogenic potential of level 3-5 (hesketh classification) on 3-5 days exclusion criteria: * hypersensitivity to adhesive plasters * contraindications to 5-ht3 receptor antagonists * clinically relevant abnormal laboratory values or hepatic, renal, infectious, neurological or psychiatric disorders or any other major systemic illness at the discretion of the investigator * any cause for nausea and vomiting other than cinv * clinically relevant abnormal ecg parameters * concomitant radiotherapy of total body, brain or upper abdomen within one week of study entry or planned during the study * a patient taking a medication to control the symptoms of a brain tumour, brain metastasis or seizure disorder